Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Link
https://link.springer.com/content/pdf/10.1007/s40262-022-01135-0.pdf
Reference77 articles.
1. Newland A, Lee E-J, McDonald V, Bussel JB. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10:9–25.
2. Kapur R. Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy. Br J Haematol. 2020;190:817–8.
3. Sakai K, Nakamura S, Sada K, Kobayashi T, Uno H, Yamamura H. Characterization of partially purified cytosolic protein-tyrosine kinase from porcine spleen. Biochem Biophys Res Commun. 1988;152:1123–30.
4. Taniguchi T, Kobayashi T, Kondo J, Takahashi K, Nakamura H, Suzuki J, et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem. 1991;266:15790–6.
5. Ku G, Malissen B, Mattei MG. Chromosomal location of the Syk and ZAP-70 tyrosine kinase genes in mice and humans. Immunogenetics. 1994;40:300–2.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database;Expert Opinion on Drug Safety;2024-08
2. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials;Annals of Hematology;2024-06-10
3. Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers;ACS Medicinal Chemistry Letters;2024-04-18
4. Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor;Journal of Pharmacology and Experimental Therapeutics;2023-11-02
5. High-throughput virtual screening of phenylpyrimidine derivatives as selective JAK3 antagonists using computational methods;Journal of Biomolecular Structure and Dynamics;2023-08-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3